Coronary Spasm after an Injection of Vincristine

Cardiotoxicity, including heart failure, thromboembolic events, and myocardial ischemia, is a concern for cardiologists and oncologists. The most frequently involved drugs are anthracyclines. We report an episode of coronary spasm due to vincristine, a vinca alkaloid, in a 49-year-old man treated fo...

Full description

Saved in:
Bibliographic Details
Published inChemotherapy (Basel) Vol. 62; no. 3; p. 169
Main Authors Gros, Rosine, Hugon, Vincent, Thouret, Jean-Marc, Peigne, Vincent
Format Journal Article
LanguageEnglish
Published Switzerland 01.01.2017
Subjects
Antineoplastic Agents, Phytogenic - adverse effects
Antineoplastic Agents, Phytogenic - therapeutic use
Carcinoma - drug therapy
Coronary Angiography
Coronary Vasospasm - diagnosis
Coronary Vasospasm - etiology
Electrocardiography
Humans
Male
Middle Aged
Neoplasms, Multiple Primary - drug therapy
Tomography, X-Ray Computed
Troponin I - analysis
Vincristine - adverse effects
Vincristine - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Cardiotoxicity, including heart failure, thromboembolic events, and myocardial ischemia, is a concern for cardiologists and oncologists. The most frequently involved drugs are anthracyclines. We report an episode of coronary spasm due to vincristine, a vinca alkaloid, in a 49-year-old man treated for a diffuse undifferentiated carcinoma. The patient suffered recurrent episodes of typical chest pain with ST-elevation in the inferior area. Coronary spasm was confirmed by an angiogram, which showed normal coronary arteries. No recurrence occurred with the medical management. Coronary spasm induced by vincristine is a newly described facet of chemotherapy-related cardiotoxicity.
ISSN:1421-9794
DOI:10.1159/000455224